RNA Targeted Therapeutics Market: Size, Trends, and Growth The RNA Targeted Therapeutics Market is experiencing rapid transformation propelled by advances in antisense oligonucleotides and siRNA delivery platforms. Sophisticated targeting approaches and emerging chemical modifications are reshaping business growth and creating new market opportunities amid evolving industry trends and regulatory landscapes. Market Size and Overview The RNA targeted therapeutics market is estimated to be valued at USD 1.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 35.4% from 2025 to 2032. Rapid adoption of second-generation antisense platforms and expansion in oncology and rare disease pipelines underpin market growth strategies. A detailed market analysis highlights diversified RNA Targeted Therapeutics Market revenue streams and emerging market segments, reinforcing robust market forecast and market report insights. Emerging modalities are diversifying RNA Targeted Therapeutics Market revenue streams across specialty segments. Use Case Scenarios • Oncology precision delivery: In late 2024, a leading biotech deployed siRNA cocktails targeting KRAS and BCL2, achieving a 40% reduction in tumor volume in pancreatic cancer trials, demonstrating strong market drivers and enhanced market share for nanoparticle platforms. • Neuromuscular disorders: Early 2025 data from spinal muscular atrophy patients treated with a novel ASO show a 2.5‐fold improvement in motor function, underscoring market dynamics and niche market opportunities within rare diseases. • Viral therapeutics: A 2024 collaboration integrated mRNA‐guided therapeutics in influenza prophylaxis, yielding a 60% reduction in viral load during phase II studies, reflecting evolving market trends and operational benefits. Policy and Regulatory Impact • FDA guidance (Q1 2025): The US FDA released draft frameworks for oligonucleotide quality control, streamlining review timelines and reducing regulatory restraints for RNA Targeted Therapeutics Market trends. • EMA updates (2024): European regulators updated Advanced Therapy Medicinal Products guidelines, mandating harmonized nonclinical dosing studies, enhancing market scope and compliance across member states. • Japan PMDA revision (2025): PMDA introduced expedited approval pathways for gene‐based therapies, catalyzing market growth and addressing supply‐chain challenges in Asia Pacific. Key Players - Abivax - AC Immune - Arrakis Therapeutics - eFFECTOR Therapeutics - Eloxx Pharmaceuticals - Alnylam Pharmaceuticals - Ionis Pharmaceuticals - Moderna - BioNTech - Wave Life Sciences - Sarepta Therapeutics - Dicerna Pharmaceuticals ‣ RNA Targeted Therapeutics Market: https://www.coherentmi.com/industry-reports/rna-targeted-therapeutics-market

Psychedelic Drugs Market Growth Trends and Forecast The Psychedelic Drugs Market is undergoing a paradigm shift driven by renewed clinical interest in serotonergic compounds and substantial private and public investment. Recent industry trends highlight a surge of Phase II trials for psilocybin and MDMA-assisted therapies, showcasing significant business growth potential across mental health and neurology segments. With high unmet clinical needs and evolving market dynamics, stakeholders are closely monitoring market opportunities and challenges, while leveraging in-depth market research and market insights to shape robust market forecast frameworks. Market Size and Overview The psychedelic drugs market is estimated to be valued at USD 3.12 Bn in 2025 and is expected to reach USD 8.50 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.4% from 2025 to 2032. Detailed Psychedelic Drugs Market report findings highlight surging clinical and regulatory drivers aiding market growth. Robust market revenue forecasts point to neurology and psychiatry segments commanding significant industry share, while evolving market drivers such as rising depression rates and novel formulations expand market scope. Key market companies are channeling R&D into niche indications, reinforcing industry size and business growth. Forecast data suggest the Psychedelic Drugs Market share will diversify as emerging molecules gain momentum. Use Case Scenarios • Psilocybin-Assisted Depression Therapy: In late 2024, a US clinic integrated psilocybin sessions into outpatient care, achieving a 60% reduction in treatment-resistant depression symptoms within eight weeks. This deployment underscores market trends toward personalized psychiatry and showcases scalable operational benefits. • MDMA-Assisted PTSD Rehabilitation: In Q1 2025, a European veterans’ hospital adopted MDMA protocols under expanded-access provisions, reporting a 45% improvement in patient-reported PTSD scales. This real-world application highlights market opportunities in mental health and validates integration of digital outcome tracking. • Microdosing for Cognitive Enhancement: In mid-2024, a tech firm launched a structured microdosing program for executives, documenting 25% gains in focus and creativity metrics over six months. This initiative reflects evolving market dynamics and novel market segments targeting corporate wellness, yielding actionable market insights for service providers. Policy and Regulatory Impact • FDA Breakthrough Therapy Designations (2024): The US FDA granted multiple breakthrough statuses for psilocybin and MDMA, accelerating clinical trials and shaping market growth strategies under streamlined review pathways. • EU PRIME Scheme Expansion (2025): The European Medicines Agency expanded its PRIority MEdicines program to include novel psychedelics, driving market research collaborations and mitigating market challenges related to development timelines. • Canadian Health Canada Exemptions (2024): Regulatory exemptions for compassionate ketamine use facilitated early access to treatments, boosting market revenue streams in psychiatric care. • Updated International Standards (2025): WHO’s draft guidelines on psychedelic quality control introduced harmonized compliance frameworks, reducing market restraints and enhancing global market dynamics. Key Players • Celon Pharma • iX Biopharma • Lykos Therapeutics • MindMed • Janssen Pharmaceuticals • Atai Life Sciences • COMPASS Pathways • Numinus Wellness • Beckley Psytech • Eleusis • Cybin • Field Trip Health • Seelos Therapeutics • Awakn Life Sciences • Delix Therapeutics ‣ Psychedelic Drugs Market: https://www.coherentmi.com/industry-reports/psychedelic-drugs-market

Accelerating Cell Cytometry Market Growth Through Innovation Industry The Cell Cytometry Market is experiencing robust business growth, driven by AI-enabled flow and image cytometry platforms introduced in 2024–2025. Advances in multiplexing and automation have reshaped industry size and market dynamics, unlocking new market opportunities across research and clinical segments. Market Size and Overview The cell cytometry market is estimated to be valued at USD 1.65 Bn in 2025 and is expected to reach USD 3.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2032. Our market insights highlight strong market growth in immunology, oncology and stem cell research segments. According to the latest Cell Cytometry Market report, automation and AI integration are key market drivers, while reagent costs act as primary market restraints. This overview underscores evolving market dynamics, market challenges, market scope, industry trends and future business growth. Use Case Scenarios • High-throughput immuno-oncology screening: In 2024, a leading biopharma deployed a spectral flow cytometer with AI analytics, boosting screening throughput by 30% and cutting reagent usage by 25%. • Stem cell therapy optimization: Early 2025 saw a CRO implement automated cell sorting for mesenchymal stem cells, raising purity from 85% to 98% in large-scale batches. • Environmental monitoring: A government lab used image cytometry in 2024 to analyze microalgae populations, enhancing detection sensitivity by 40%. These real-world deployments reveal major market opportunities and validate deep market analysis. Policy and Regulatory Impact • EU In Vitro Diagnostic Regulation (IVDR), May 2024: Enforced stricter validation protocols for cytometry reagents, addressing market restraints and harmonizing compliance with international standards. • FDA’s 2025 guidance on flow cytometry assays: Released February 2025, it outlines streamlined approval pathways, driving Cell Cytometry Market trends toward clinical diagnostics and bolstering market growth strategies. • China’s 2024 Biosafety Framework update: Tightened facility requirements for cytometry labs, reshaping market dynamics and introducing new regulatory challenges for instrument and reagent providers. Key Players Key market companies driving innovation: • Agilent Technologies • Becton Dickinson • Beckman Coulter Life Sciences • Bio-Rad Laboratories • Thermo Fisher Scientific • Miltenyi Biotec • Sysmex Corporation • Sartorius AG • Luminex Corporation • PerkinElmer Inc. • Tecan Group Ltd. • NanoString Technologies ‣ Cell Cytometry Market: https://www.coherentmi.com/industry-reports/cell-cytometry-market

Blockchain Technology in Healthcare Market Growth and Trends The Blockchain Technology in Healthcare Market is undergoing rapid transformation as decentralized ledgers enhance data security and patient trust. Leading blockchain vendors are capturing significant industry share by focusing on secure consent management and interoperability. Expert market analysis highlights that evolving health IT architectures are expanding the industry size and driving robust business growth. Market Size and Overview The blockchain technology in healthcare market is estimated to be valued at USD 194.5 Mn in 2025 and is expected to reach USD 796.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 22.3% from 2025 to 2032. According to the latest Blockchain Technology in Healthcare Market, surging investments in secure data sharing are among the primary market drivers. The Blockchain Technology in Healthcare Market revenue trajectory reflects partnerships between tech vendors and hospital networks, amplifying service integration. Emerging Blockchain Technology in Healthcare Market trends include AI-enabled smart contracts and cross-border data exchanges. This market size growth is further fueled by rising telemedicine adoption and secure consent mechanisms. Recent market report analyses emphasize shifts in reimbursement models and data monetization strategies. Despite consolidation, market share concentration remains moderate, indicating room for new entrants. Projected market revenue uplift aligns with increased public funding for health IT modernization. Use Case Scenarios • Pharmaceutical supply chain integrity: In mid-2024, a leading global pharmaceutical company piloted blockchain-based cold-chain tracking, reducing counterfeit incidents by 40% and accelerating recall processes by 25%. • Patient data management: Late-2024 saw a regional hospital network deploy a blockchain identity solution, cutting data breach incidents by 60% and streamlining consent audits across 15 clinics. • Clinical trials optimization: Early 2025, a biotech firm implemented smart-contract-driven trial enrolment, trimming administrative overhead by 30% and speeding protocol amendments by 18%. Policy and Regulatory Impact • EU EHR Interoperability Guidelines (July 2024) now mandate blockchain audit trails for patient records, prompting healthcare providers to allocate 15% more budget toward compliance. • US FDA Draft Guidance on Distributed Ledger Tech (Q1 2025) clarifies validation frameworks for blockchain in clinical trials, reducing time-to-approval by 20%. • ISO 22739:2025 Update standardized blockchain terminology in healthcare, facilitating cross-border data exchange and widening the market scope for global vendors. • South Korea’s Health Data Act (Dec 2024) introduced incentives for blockchain-secured patient registries, driving regional market growth by an estimated 12%. Key Players 1. ConsenSys 2. Embleema 3. Equideum Health 4. IBM Life Sciences 5. MELLODDY 6. Guardtime 7. BurstIQ 8. Chronicled 9. Simply Vital Health 10. Solve.Care 11. PokitDok 12. Medicalchain 13. FarmaTrust 14. VeChain 15. Modum 16. Iryo ‣ Blockchain Technology in Healthcare Market: https://www.coherentmi.com/industry-reports/blockchain-technology-in-healthcare-market

https://www.silverskills.com/digital-transformation/industries/healthcare-and-life-sciences/

https://www.silverskills.com/digital-transformation/industries/healthcare-and-life-sciences/

https://www.silverskills.com/digital-transformation/industries/healthcare-and-life-sciences/

‘Humans will live up to 200 years in next 40 years’ A renowned medical expert, Dr. Ibrahim Wada, has predicted that humans will live up to 200 years in the next 40 years. Dr. Wada is the Founder of Nisa Medical Group, Abuja, and an Associate Professor of Obstetrics and Gynaecology at the Abubakar Tafawa Balewa University in Bauchi. The professor made this prediction during the Second Nimi Dimkpa Briggs Legacy Lecture Series, recently held at the University of Port Harcourt. While delivering a speech on “The Longevity of Man”, Dr. Wada highlighted the rapid advancements in medical technology and genetic engineering. He noted that scientists can now create artificial eggs and sperm from human saliva and grow babies in artificial wombs. Rats have already been born with the aid of this technology, and Dr Wada believes it is only a matter of time before humans begin to utilise the technology. Dr. Wada also discussed the potential of stem cells, artificial organs, and genetic reprogramming to extend human lifespan. He said, “In another 40 or 30 years, it will be normal for a child to say I am going to be here for 200 years and another is going to say maybe 250 years. “We are in a computer reprogramming age of man.” The renowned medical expert further noted that advancements in life sciences have made it possible for people to understand and manipulate the codes in human genes that determine longevity by recreating stem cells from one’s gene and reintroducing them to one’s body to regenerate the dead cell. According to Dr. Wada, life science has developed to a stage where one can understand all those codes and even manipulate some of them to achieve longevity. He, however, lamented that such advanced healthcare services are not yet available in Nigeria. Regardless of the absence of the service in Nigeria, Dr. Wada emphasised the importance of healthcare services, noting that medical check-ups and lifestyle changes can help Nigerians achieve longevity. He advised people to prioritise their health by eating well, exercising regularly, and getting enough rest. “The brain is always active, and when it’s time to rest, you must rest the brain, no compromise. Those are the elements that will make you live very long,” said Dr. Wada.

Download Sample & Read More: https://www.renub.com/malaysia-game-based-learning-market-p.php The Malaysia game-based learning market size was around USD 104.26 million in 2024 and is anticipated to grow to around USD 434.97 million in 2033, with a CAGR of 17.20% between 2025 and 2033. The market is expanding due to the growing uptake of digital learning tools, technological advancements, and incorporation of gamification in training and educational methods in all sectors. The report Malaysia Game-Based Learning Market Forecast covers by Game Type (Training, Knowledge & skill-based Games, Assessment & Evaluation Games, AI-based Games, AR VR Games, Language Learning Games), Deployment Type (On Premise, Cloud), End User (Education, Consumer, Healthcare & Life Sciences, Retail, Government, IT & Telecom, Manufacturing, Others), Company Analysis 2025-2033. #Malaysia_Game_Based_Learning_Market #Malaysia_Game_Based_Learning_Market_Size #Malaysia_Game_Based_Learning_Market_Trends #Malaysia_Game_Based_Learning_Market_Share

https://www.silverskills.com/digital-transformation/industries/healthcare-and-life-sciences/